ReviewClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2025
New Topical and Systemic Treatments for Atopic Dermatitis.
Review in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Gram-Positive and Gram-Negative Probiotic Extracellular Vesicles: Mechanisms of Immune Modulation and Therapeutic Opportunities in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
- The JAK-STAT pathway in allergic diseases: from pathogenesis to targeted therapy.Biomarker research · 2026Review
- Preformulation Studies and Rational Design of an Ointment Containing a Postbiotic Metabolite of Procyanidins for Topical Use.Pharmaceutics · 2026Article
- Anti-Inflammatory Evaluation of Pyrazino[2,1-Pharmaceuticals (Basel, Switzerland) · 2026Article
- Bifidobacterium Breve Yang08 Alleviates Atopic Dermatitis By Enriching Akkermansia Muciniphila and Inhibiting Neutrophil Extracellular Traps Formation In Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Global research trends on the aryl hydrocarbon receptor in atopic dermatitis: a bibliometric and visualized analysis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis is an inflammatory skin condition characterised by pruritus and a chronic relapsing-remitting course. Previous topical and systemic treatments for atopic dermatitis were broadly immunosuppressive, which limited their long-term use. Recently, more targeted therapies for atopic dermatitis have been developed. In this review, we discuss the efficacy and safety of new therapies, including topical PDE4 (phosphodiesterase 4) inhibitors, a topical aryl hydrocarbon receptor agonist, topical and systemic JAK (Janus kinase) inhibitors and biologics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.